Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BioMarin Pharmaceutical ( (BMRN) ) has provided an announcement.
On May 16, 2025, BioMarin Pharmaceutical Inc. announced an agreement to acquire Inozyme Pharma, Inc. for approximately $270 million. This acquisition aims to enhance BioMarin’s enzyme therapy portfolio by adding INZ-701, a late-stage enzyme replacement therapy for ENPP1 Deficiency, a rare genetic condition. The transaction is expected to close in the third quarter of 2025, pending regulatory approval and other conditions. The acquisition is strategically significant for BioMarin, as it aligns with their commitment to advancing treatments for serious genetic conditions, potentially offering the first treatment for ENPP1 Deficiency. The first pivotal data readout for INZ-701 in children is anticipated in early 2026, with a potential launch in 2027, marking a significant step forward in addressing unmet medical needs.
The most recent analyst rating on (BMRN) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.
Spark’s Take on BMRN Stock
According to Spark, TipRanks’ AI Analyst, BMRN is a Outperform.
BioMarin Pharmaceutical is well-positioned with strong financial performance, highlighted by robust revenue and profit growth, and a solid balance sheet. Technical analysis suggests caution with bearish indicators, but valuation remains reasonable given growth expectations. The positive sentiment from the earnings call supports the company’s strategic positioning and operational strength. Challenges include managing VOXZOGO’s revenue dynamics and tariff exposure, but overall, the outlook remains optimistic.
To see Spark’s full report on BMRN stock, click here.
More about BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. is a global biotechnology company based in San Rafael, California, founded in 1997. It focuses on developing innovative medicines for genetically defined conditions, with a portfolio of eight commercial therapies and a robust clinical pipeline. The company aims to leverage genetic science to create transformative treatments for patients worldwide.
Average Trading Volume: 1,764,297
Technical Sentiment Signal: Sell
Current Market Cap: $11.26B
For detailed information about BMRN stock, go to TipRanks’ Stock Analysis page.